Pharmaceutical Commerce

JULY 31, 2025

4 Meanwhile, Jim Shehan, chair of the FDA regulatory practice at Lowenstein Sandler, expressed 5 his concern to me, noting that “we do know that a very large percentage of the recent deal making has been in licensing of Chinese drugs by the global pharmaceutical industry. It depends on what you're doing.”

Insurance

Pharmacy Times

JULY 18, 2025

Rumore, PharmD, Esq, MS, LLM, FAPhA Key Takeaways The removal of tirzepatide and semaglutide from the FDA's shortage list impacts 503A compounders, requiring adherence to complex legal and regulatory frameworks. SHOW MORE GLP-1 compounding faces legal challenges, evolving FDA rules, and heightened enforcement risks.

Compounding

Omnicell

SEPTEMBER 5, 2022

In fact, in a 2020 ISMP Sterile Compounding Pulse Check conducted with 634 pharmacy practitioners, only 25% of respondents report using technologies that include barcode verification, images, and gravimetric verification for 50% of compounded sterile products.

Compounding